Trials / Completed
CompletedNCT02501200
CKD-391 Pharmacokinetic Study Phase I
Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
Detailed description
To compare the CKD-391 (Experimental product) to the dose Atorvastatin calcium and Ezetimibe combination in health male subjects is the purpose of this trial. Following are evaluated in this trial; Characteristics and safety/Tolerability Of CKD-391.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-391 | Investigational product is prescribed to all of randomized subjects for two times. |
| DRUG | Atrovastatin and Ezetimibe combination therapy | Investigational products are prescribed to all of radomized subjects for two times. |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-07-17
- Last updated
- 2016-12-26
Source: ClinicalTrials.gov record NCT02501200. Inclusion in this directory is not an endorsement.